Anavex reports Q3 EPS (16c) vs (14c) last year

“Our development of non-invasive, targeted upstream compounds continues to advance, particularly in the context of Alzheimer’s disease,” said Christopher U. Missling, PhD, President and CEO of Anavex (AVXL). “Clinical feedback highlights the importance of orally administered therapies that are both accessible and effective. At AAIC 2025, we presented open-label extension data for blarcamesine, which demonstrated continued clinically meaningful benefit in early-stage Alzheimer’s patients-further validating its therapeutic potential.”